Christophe Homer
Seminars
Monday 22nd September 2025
Creating Order from Chaos – The Path to Standardizing Minimal Residual Disease (MRD)
3:50 pm
- Learning from history: Over the past 10 years the CDx space has seen the entry of numerous novel biomarkers whose results are more nuanced that the binary YES / NO of a traditional genetic test. PD-L1, TMB and MSI provide great examples of the challenges that novel biomarkers have faced when entering the market, especially with regards to standardization and uptake
- Understanding the present: MRD is a novel biomarker that helps to monitor the risk of relapse in oncology post treatment. Although MRD shows great potential, inconsistencies and a lack of standardisation with regards to methods, procedures, sensitivity and interpretation of results, make the implementation of MRD an ongoing challenge.
- Shaping the future: Learning from previous analogues can help us to understand how to plot a path towards the standardization of MRD more quickly and efficiently, providing greater clarity for physicians and better outcomes for patientsÂ
